Ernst Holler
Overview
Explore the profile of Ernst Holler including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
251
Citations
8517
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Meyers G, Hamadani M, Martens M, Ali H, Chevallier P, Choe H, et al.
Bone Marrow Transplant
. 2025 Feb;
PMID: 40016514
No abstract available.
2.
Katsivelos N, Spyrou N, Weber D, Vasova I, Ayuk F, Choe H, et al.
Transplant Cell Ther
. 2024 Dec;
31(1):10.e1-10.e9.
PMID: 39667999
Background: The standard treatment for acute graft-vs-host disease (GVHD), a common complication following allogeneic hematopoietic cell transplant, remains prolonged courses of high dose corticosteroids. Previous attempts to decrease corticosteroid exposure...
3.
Turner A, Li L, Monk I, Lee J, Ingle D, Portelli S, et al.
Nature
. 2024 Oct;
635(8040):969-977.
PMID: 39443798
Multidrug-resistant bacterial pathogens like vancomycin-resistant Enterococcus faecium (VREfm) are a critical threat to human health. Daptomycin is a last-resort antibiotic for VREfm infections with a novel mode of action, but...
4.
Weber D, Meedt E, Poeck H, Thiele-Orberg E, Hiergeist A, Gessner A, et al.
Visc Med
. 2024 Jul;
:1-6.
PMID: 39047173
Background: Acute graft-versus-host disease (GvHD) is a major and sometimes lethal complication following allogeneic stem cell transplantation (aSCT). In the last 10 years, a massive loss of microbiota diversity with...
5.
Denk A, Edinger M, Weber D, Holler E, Fante M, Meedt E, et al.
Ann Hematol
. 2024 Jun;
103(8):3071-3081.
PMID: 38916740
Steroid-refractory acute graft-versus-host disease (aGvHD) is a serious complication after allogeneic hematopoietic stem cell transplantation, associated with significant mortality. Ruxolitinib was the first drug approved for aGvHD, based on results...
6.
DeFilipp Z, Kim H, Spyrou N, Katsivelos N, Kowalyk S, Eng G, et al.
Blood Adv
. 2024 Apr;
8(13):3488-3496.
PMID: 38640197
The significance of biomarkers in second-line treatment for acute graft-versus-host disease (GVHD) has not been well characterized. We analyzed clinical data and serum samples at the initiation of second-line systemic...
7.
Etra A, Jurdi N, Katsivelos N, Kwon D, Gergoudis S, Morales G, et al.
Blood Adv
. 2024 Apr;
8(12):3284-3292.
PMID: 38640195
Graft-versus-host disease (GVHD) is a major cause of nonrelapse mortality (NRM) after allogeneic hematopoietic cell transplantation. Algorithms containing either the gastrointestinal (GI) GVHD biomarker amphiregulin (AREG) or a combination of...
8.
Qayed M, Kapoor U, Gillespie S, Westbrook A, Aguayo-Hiraldo P, Ayuk F, et al.
Transplant Cell Ther
. 2024 Mar;
30(6):603.e1-603.e11.
PMID: 38548227
Acute graft versus host disease (GVHD) is a common and serious complication of allogeneic hematopoietic cell transplantation (HCT) in children but overall clinical grade at onset only modestly predicts response...
9.
Schreiber L, Ghimire S, Hiergeist A, Renner K, Althammer M, Babl N, et al.
Front Immunol
. 2024 Mar;
15:1347835.
PMID: 38495883
Vitamin D3 regulates a variety of biological processes irrespective of its well-known importance for calcium metabolism. Epidemiological and animal studies indicate a role in immune regulation, intestinal barrier function and...
10.
Rosenberger A, Crossland R, Dressel R, Kube D, Wolff D, Wulf G, et al.
Front Immunol
. 2024 Feb;
15:1280876.
PMID: 38384455
Introduction: Data on genomic susceptibility for adverse outcomes after hematopoietic stem cell transplantation (HSCT) for recipients are scarce. Methods: We performed a genome wide association study (GWAS) to identify genes...